New Inspire study with Takeda Pharmaceuticals sheds light on rare neuromuscular diseases
A poster presentation at IgNS 2023 titled “Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patient Journey and Experience: A Qualitative Study” helped illuminate the challenges faced by CIDP and MMN patients. The study, which was a collaboration between Inspire, Takeda Pharmaceuticals, and leading CIDP medical experts Dr. Allen and Dr. Karam, aims to bridge the knowledge gap surrounding CIDP and MMN.
As part of this qualitative study, Inspire and collaborating researchers explored the patient experience of both MMN and CIDP, including the diagnostic and treatment journey, burden of illness, and communications with physicians related to diagnosis and disease management. The study also seeks to identify unmet needs related to care of MMN and CIDP.
The study revealed a difficult journey to accurate diagnosis with significant impacts on quality of life, as well as unmet needs in patient education and effective treatment.
